中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
19期
29-30
,共2页
达英-35%二甲双胍%多囊卵巢综合征%分娩结局
達英-35%二甲雙胍%多囊卵巢綜閤徵%分娩結跼
체영-35%이갑쌍고%다낭란소종합정%분면결국
diane-35%metformin%polycystic ovary syndrome(PCOS)%pregnancy and delivery outcomes
目的：观察达英－35联合二甲双胍治疗多囊卵巢综合征（PCOS）的疗效以及对女性妊娠分娩结局的影响。方法选择PCOS患者112例，采取随机数字表法均分为观察组和对照组，对照组给予达英－35治疗，观察组在对照组基础上联合二甲双胍治疗，记录两组临床疗效。结果观察组治疗后黄体生成素为（7.01±2.13）mU/mL、黄体生成素/卵泡刺激素比值为（1.02±0.11）、胰岛素抵抗指数为（2.23±0.06）；对照组治疗后黄体生成素为（10.05±3.98）mU/mL、黄体生成素/卵泡刺激素比值为（1.75±0.49）、胰岛素抵抗指数为（3.14±0.38）。观察组治疗后卵巢体积为（7.13±0.68）mL，窦卵细胞数目为（4.33±1.21）个，内膜厚度为（9.96±1.95）mm；对照组治疗后卵巢体积为（9.96±1.37）mL，窦卵细胞数目为（7.89±2.44）个，内膜厚度为（7.32±1.49）mm。观察组随访后排卵51例，妊娠成功45例，流产2例，新生儿死亡0例；对照组随访后排卵39例，妊娠成功21例，流产13例，新生儿死亡5例。组间对比，差异均有统计学意义（ P﹤0.05）。结论达英－35联合二甲双胍治疗PCOS，可有效改善患者内分泌状况，促进子宫内膜生长，恢复卵泡成熟与排卵，提高患者妊娠成功率，降低流产率，值得临床推广。
目的：觀察達英－35聯閤二甲雙胍治療多囊卵巢綜閤徵（PCOS）的療效以及對女性妊娠分娩結跼的影響。方法選擇PCOS患者112例，採取隨機數字錶法均分為觀察組和對照組，對照組給予達英－35治療，觀察組在對照組基礎上聯閤二甲雙胍治療，記錄兩組臨床療效。結果觀察組治療後黃體生成素為（7.01±2.13）mU/mL、黃體生成素/卵泡刺激素比值為（1.02±0.11）、胰島素牴抗指數為（2.23±0.06）；對照組治療後黃體生成素為（10.05±3.98）mU/mL、黃體生成素/卵泡刺激素比值為（1.75±0.49）、胰島素牴抗指數為（3.14±0.38）。觀察組治療後卵巢體積為（7.13±0.68）mL，竇卵細胞數目為（4.33±1.21）箇，內膜厚度為（9.96±1.95）mm；對照組治療後卵巢體積為（9.96±1.37）mL，竇卵細胞數目為（7.89±2.44）箇，內膜厚度為（7.32±1.49）mm。觀察組隨訪後排卵51例，妊娠成功45例，流產2例，新生兒死亡0例；對照組隨訪後排卵39例，妊娠成功21例，流產13例，新生兒死亡5例。組間對比，差異均有統計學意義（ P﹤0.05）。結論達英－35聯閤二甲雙胍治療PCOS，可有效改善患者內分泌狀況，促進子宮內膜生長，恢複卵泡成熟與排卵，提高患者妊娠成功率，降低流產率，值得臨床推廣。
목적：관찰체영－35연합이갑쌍고치료다낭란소종합정（PCOS）적료효이급대녀성임신분면결국적영향。방법선택PCOS환자112례，채취수궤수자표법균분위관찰조화대조조，대조조급여체영－35치료，관찰조재대조조기출상연합이갑쌍고치료，기록량조림상료효。결과관찰조치료후황체생성소위（7.01±2.13）mU/mL、황체생성소/란포자격소비치위（1.02±0.11）、이도소저항지수위（2.23±0.06）；대조조치료후황체생성소위（10.05±3.98）mU/mL、황체생성소/란포자격소비치위（1.75±0.49）、이도소저항지수위（3.14±0.38）。관찰조치료후란소체적위（7.13±0.68）mL，두란세포수목위（4.33±1.21）개，내막후도위（9.96±1.95）mm；대조조치료후란소체적위（9.96±1.37）mL，두란세포수목위（7.89±2.44）개，내막후도위（7.32±1.49）mm。관찰조수방후배란51례，임신성공45례，유산2례，신생인사망0례；대조조수방후배란39례，임신성공21례，유산13례，신생인사망5례。조간대비，차이균유통계학의의（ P﹤0.05）。결론체영－35연합이갑쌍고치료PCOS，가유효개선환자내분비상황，촉진자궁내막생장，회복란포성숙여배란，제고환자임신성공솔，강저유산솔，치득림상추엄。
Objective Discussion of the Diane-35 and the curative effect of metformin in the treatment of PCOS and influence the outcome of the pregnancy childbirth to women. Methods Choose our hospital treatment of 112 cases of patients with PCOS to random number table method was divided into observation group and control group, control group given Diane-35treatment, the observation group in the control group based on the joint of metformin the treatment, two groups of clinical curative effect. Results Observation group af-ter treatment luteinizing hormone ( 7. 01 ± 2. 13 ) mU/mL, luteinizing hormone and follicle estrogen ratio ( 1. 02 ± 0. 11 ) , insulin resistance index ( 2. 23 ± 0. 06 );The control group after treatment luteinizing hormone ( 10. 05 ± 3. 98 ) mU/mL, luteinizing hormone and follicle es-trogen ratio ( 1. 75 ± 0. 49 ) , insulin resistance index ( 3. 14 ± 0. 38 ) , comparing differences between groups was statistically significant ( P ﹤ 0. 05 ) . Observation group after treatment of ovarian volume ( 7. 13 ± 0. 68 ) mL, sinus egg number ( 4. 33 ± 1. 21 ) , endometrial thick-ness ( 9. 96 ± 1. 95 ) mm; The control group after treatment of ovarian volume ( 9. 96 ± 1. 37 ) mL, sinus egg number ( 7. 89 ± 2. 44 ) , en-dometrial thickness ( 7. 32 ± 1. 49 ) mm, comparing differences between groups was statistically significant ( P ﹤ 0. 05 ) . Observation group follow-up after ovulation 51 cases, 45 cases of successful pregnancy, abortion in 2 cases, neonatal death case 0;The control group after the follow-up 39 cases, ovulation pregnancy success 21 cases, 13 cases of abortion, neonatal death in 5 cases, comparing differences be-tween groups was statistically significant ( P ﹤ 0. 05 ) . Conclusion Diane-35 and metformin treatment of patients with PCOS can ef-fectively improve the endocrine situation, promote the growth of endometrium, and recovery in patients with ovarian follicles maturity and ovulation, and improve the success rate of patients with pregnancy, reduces the abortion rate, is worth popularizing in clinical use.
